OBJECTIVES: Schizophrenia patients have noticeably higher smoking rates, higher nicotine dependence levels as well as lower smoking cessation rates compared to the general population. The objective of this study was to summarize the current evidence for efficacy of smoking cessation medications (nicotine replacement therapy, Bupropion SR, or Varenicline) as treatments for nicotine dependence in patients with schizophrenia. METHODS: A similar Cochrane review and searching terms was published in 2010 but no study with Varenicline was available at that time because of its more recent FDA approval. Consequently, we first conducted a search for randomized controlled trials of NRT, Bupropion SR, or Varenicline in adult smokers with schizophrenia that was published after 2010. Studies were searched with Medline (Ovid), PubMed (National Library of Medicine), Embase (Ovid), and PsycINFO (Ovid). Definition of abstinence was 8-14 weeks after the cessation treatment starts. Only studies with abstinence measured within this range were included. Studies were then combined together with the studies in Cocharne review with similar outcome definition. RESULTS: Seven original studies were included in this review (1 for NRT, 4 for Bupropion SR, and 2 for Varenicline). Majority of the medications achieved smoking cessation with a higher percentage as compared to placebo but most of the effects were not statistically significant. No significant changes in mental states were observed after the cessation treatments exposure.   CONCLUSIONS: Our review showed that most of the cessation medications slightly improved abstinence rates compared to placebo after 8 - 14 weeks of treatment, but this did not reach statistical significance. Only seven original studies were included due to limited available randomized controlled trials. Future studies could consider smoking reduction as an outcome as reaching abstinence might be difficult to achieve among schizophrenia patients.